Skip to main content

Alport Syndrome

3
Pipeline Programs
8
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 10 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY 3401016Phase 2
ENYO Pharma
ENYO PharmaFrance - Lyon
1 program
1
VonafexorPhase 21 trial
Active Trials
NCT06425055Completed26Est. Nov 2025
Calliditas Therapeutics
Calliditas TherapeuticsSweden - Stockholm
1 program
1
SetanaxibPhase 1/21 trial
Active Trials
NCT06274489Completed20Est. Jun 2025
Sandoz
SandozAustria - Kundl
2 programs
Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesN/A1 trial
Urinary Biomarkers of the Progression of Alport Kidney DiseaseN/A1 trial
Active Trials
NCT01602835Terminated80Est. May 2013
NCT01705132Completed80Est. Jul 2013
Novartis
NovartisBASEL, Switzerland
2 programs
Human Urine Sample Collection for Alport Nephropathy Biomarker StudiesN/A
Urinary Biomarkers of the Progression of Alport Kidney DiseaseN/A
Sanofi
SanofiPARIS, France
2 programs
RG012PHASE_11 trial
lademirsenPHASE_2RNA Therapeutic1 trial
Active Trials
NCT03373786Completed4Est. May 2019
NCT02855268Terminated43Est. Sep 2022
Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
Longitudinal data collectionN/A1 trial
Active Trials
NCT06526741RecruitingEst. Aug 2048
Eloxx Pharmaceuticals
1 program
ELX-02PHASE_21 trial
Active Trials
NCT05448755Completed3Est. Sep 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ENYO PharmaVonafexor
Eloxx PharmaceuticalsELX-02
Sanofilademirsen
Calliditas TherapeuticsSetanaxib
SanofiRG012
Pulse BiosciencesLongitudinal data collection
SandozHuman Urine Sample Collection for Alport Nephropathy Biomarker Studies
SandozUrinary Biomarkers of the Progression of Alport Kidney Disease

Clinical Trials (8)

Total enrollment: 256 patients across 8 trials

NCT06425055ENYO PharmaVonafexor

Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

Start: Aug 2024Est. completion: Nov 202526 patients
Phase 2Completed
NCT05448755Eloxx PharmaceuticalsELX-02

A Study of ELX-02 in Patients With Alport Syndrome

Start: Nov 2022Est. completion: Sep 20233 patients
Phase 2Completed
NCT02855268Sanofilademirsen

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Start: Nov 2019Est. completion: Sep 202243 patients
Phase 2Terminated
NCT06274489Calliditas TherapeuticsSetanaxib

A Study to Evaluate Setanaxib in Patients With Alport Syndrome

Start: Nov 2023Est. completion: Jun 202520 patients
Phase 1/2Completed
NCT03373786SanofiRG012

A Study of RG-012 in Subjects With Alport Syndrome

Start: Dec 2017Est. completion: May 20194 patients
Phase 1Completed
NCT06526741Pulse BiosciencesLongitudinal data collection

ASF Alport Patient Registry

Start: Aug 2023Est. completion: Aug 2048
N/ARecruiting
NCT01602835SandozHuman Urine Sample Collection for Alport Nephropathy Biomarker Studies

Human Urine Sample Collection for Alport Nephropathy Biomarker Studies

Start: Sep 2012Est. completion: May 201380 patients
N/ATerminated
NCT01705132SandozUrinary Biomarkers of the Progression of Alport Kidney Disease

Urinary Biomarkers of the Progression of Alport Kidney Disease

Start: Jun 2012Est. completion: Jul 201380 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 256 patients
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.